Explore the vast range of titles available.

Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure. The SELECT trial was a randomised, double-blind, multicentre, placebo-controlled, event-driven phase 3 trial in 41 countries. Adults aged 45 years and older, with a BMI of 27 kg/m2 or greater and established cardiovascular disease were eligible for the study. Patients were randomly assigned (1:1) with a block size of four using an interactive web response system in a double-blind manner to escalating doses of once-weekly subcutaneous semaglutide over 16 weeks to a target dose of 2·4 mg, or placebo. In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure at enrolment, subclassified as heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, or unclassified heart failure. Endpoints comprised MACE (a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); a composite heart failure outcome (cardiovascular death or hospitalisation or urgent hospital visit for heart failure); cardiovascular death; and all-cause death. The study is registered with ClinicalTrials.gov, NCT03574597. Between Oct 31, 2018, and March 31, 2021, 17 604 patients with a mean age of 61·6 years (SD 8·9) and a mean BMI of 33·4 kg/m2 (5·0) were randomly assigned to receive semaglutide (8803 [50·0%] patients) or placebo (8801 [50·0%] patients). 4286 (24·3%) of 17 604 patients had a history of investigator-defined heart failure at enrolment: 2273 (53·0%) of 4286 patients had heart failure with preserved ejection fraction, 1347 (31·4%) had heart failure with reduced ejection fraction, and 666 (15·5%) had unclassified heart failure. Baseline characteristics were similar between patients with and without heart failure. Patients with heart failure had a higher incidence of clinical events. Semaglutide improved all outcome measures in patients with heart failure at random assignment compared with those without heart failure (hazard ratio [HR] 0·72, 95% CI 0·60–0·87 for MACE; 0·79, 0·64–0·98 for the heart failure composite endpoint; 0·76, 0·59–0·97 for cardiovascular death; and 0·81, 0·66–1·00 for all-cause death; all pinteraction>0·19). Treatment with semaglutide resulted in improved outcomes in both the heart failure with reduced ejection fraction (HR 0·65, 95% CI 0·49–0·87 for MACE; 0·79, 0·58–1·08 for the composite heart failure endpoint) and heart failure with preserved ejection fraction groups (0·69, 0·51–0·91 for MACE; 0·75, 0·52–1·07 for the composite heart failure endpoint), although patients with heart failure with reduced ejection fraction had higher absolute event rates than those with heart failure with preserved ejection fraction. For MACE and the heart failure composite, there were no significant differences in benefits across baseline age, sex, BMI, New York Heart Association status, and diuretic use. Serious adverse events were less frequent with semaglutide versus placebo, regardless of heart failure subtype. In patients with atherosclerotic cardiovascular diease and overweight or obesity, treatment with semaglutide 2·4 mg reduced MACE and composite heart failure endpoints compared with placebo in those with and without clinical heart failure, regardless of heart failure subtype. Our findings could facilitate prescribing and result in improved clinical outcomes for this patient group. Novo Nordisk.

Using a high-quality electronic medical record (EMR) integrated with a high-quality practice management system is the future of medicine. In an era of stagnant reimbursement rates, skyrocketing overhead costs and higher levels of accountability, medical offices need to use technology to streamline work, increase efficiencies, improve documentation, decrease malpractice risk and improve profitability. One of the major benefits of EMRs is the increased efficiency they offer. EMR's alert system helps ensure that physicians do not forget important tests, such as a repeat chest CT every four months to follow up on someone's pulmonary nodule or a repeat colonoscopy in three years to recheck a patient's colon polyps, thereby providing both medical-legal benefits and improvements in quality of care. There is no waiting for staff to enter charges from paper superbills into the practice management system. Despite the start-up cost, EMR has provided an excellent return on investment -- the gift that keeps on giving.

MLR-1023, called Tolimidone when evaluated unsuccessfully by Pfizer for gastric ulcer disease, has been repurposed as a novel oral insulin sensitizer with its effects mediated by selective activation of Lyn kinase. We aimed to evaluate the optimal dose, efficacy and safety of MLR-1023 in patients with type 2 diabetes. Type 2 diabetes patients (18–75 years) on diet/exercise therapy were randomized and double-blinded to receive MLR-1023 (100-mg or 200-mg, once-daily [qd] or twice-daily [bid]) or matching placebo for 28 days. The primary endpoint was postprandial glucose (PPG) area under the curve (AUC0–3h) in a mixed meal tolerance test (MMTT) at day 29. Secondary endpoints included changes in fasting plasma glucose (FPG), insulin, HbA1c, lipids and body weight and adverse events. ANCOVA model was used for efficacy analysis. The placebo-corrected least-squares mean differences (ΔLSM) in MMTT PPG AUC0-3 h (mmol/L) were −5.96 and −5.6 (both p = 0.03) in the MLR-1023 100-mg qd and 100-mg bid groups, respectively. The placebo-corrected ΔLSM in FPG (mmol/L) was −2.34 (p = 0.003) in the MLR-1023 100-mg qd group. Triglycerides improved with MLR-1023 (ΔLSM, −0.56 mmol/L, p = 0.07 and −0.59 mmol/L, p = 0.05) in the 200mgqd and 200 mg bid groups, respectively. Reductions in fasting insulin, HbA1c and body weight were not statistically significant. Most common adverse events with MLR-1023 treatment were headache (4.2%) and somnolence (2.5%). MLR-1023 100-mg once-daily for 4 weeks was the most effective dose with significant reduction in PPG AUC following a MMTT. MLR-1023 was safe and well-tolerated in patients with type 2 diabetes. Clinical Trials Registration Number: NCT02317796 •Type 2 diabetes prevalence is increasing, and anti-diabetic agents with improved benefit-risk profiles are needed.•The underlying cause of type 2 diabetes is insulin resistance.•Present insulin sensitizers, thiazolidinediones, stimulate PPAR gamma, increase adipogenesis, and cause weight gain.•MLR-1023 represents a new category of sensitizers that does not stimulate PPARs and is not associated with weight gain.•MLR-1023, a Lyn kinase agonist, is safe, effective and well-tolerated in treating type 2 diabetes.

Introduction: Chronic constipation is a multifactorial gastrointestinal (GI) disorder. Although several treatments are available, many patients remain dissatisfied and desire new therapies. The orally administered intraluminal vibrating capsule (VC) (Vibrant Ltd., Yokneam, Israel) is the first chemical-free treatment that improves constipation by mechanically inducing vibrations. Our aim was to determine the effects of VC on complete spontaneous bowel movements (CSBMs) in patients with chronic idiopathic constipation (CIC), using 2 paradigms of VC activation. Methods: Patients with CIC who fulfilled Rome III criteria were enrolled in 2 double-blind, sham-controlled studies. Subjects ingested 5 capsules per week for 8 weeks. Patients in study 1 (n=182) received a single vibration session, and in study 2 (n=63) multiple (3) vibration sessions/day using similar frequency in both studies. B owel symptoms were recorded on daily stool diary. Results: Data on CSBM frequency from the 2 studies were pooled for this analysis. A significant correlation was found with single vibration (study 1) between the time of pre-defined vibration and the frequency of occurrence of CSBM over 24 hours (figure 1). The number and percentage of CSBMs were higher in the active arm (p<0.0018) compared to sham arm (figure 1), and coincided with the timing of vibration as preprogrammed for the capsule (8-12 hours from administration 1st peak). In addition although there is sham response (natural circadian rhythm), it drops dramatically the next morning, (hours 34-36), while VC active arm shows greater activity during that time (24 hours from last vibration) (figure 2). In study 2, because of multiple vibration sessions, 2 peaks were seen: 1st peak around 8-12 hours followed by a 2nd peak around evening time (figure 3). Significant clinical correlation was found with multiple vibration sessions and CSBM (p<0.0357). Conclusion: VC significantly increases the number of CSBMs when compared to sham and this coincides with VC activation. This observation suggests that the mechanism of action of VC is to induce bowel movements through mechanical vibration of the colon, augmenting colonic biorhythm and peristalsis. This unique, non-pharmaceutical modality could be a novel approach for constipation.

Mediation programs have proliferated in recent years, and at some point, virtually every franchise dispute has a date with a mediator. Lawyers and their clients can engage in bad faith tactics while simultaneously using mediation jargon to appear sincerely interested in settling a dispute. Many mediation orders require a party representative with full settlement authority to personally-attend the mediation. Recommendations to franchise business executives and their counsel who are ordered to mediate: 1. Show up with a representative who knows the case ad can speak for the company. 2. Show up with a reasoned position. 3. If you do not intend to settle, tell the mediator and other side before the mediation so you don;t waste everyone's time, including your own.

In some situations, an involuntary bankruptcy filing can help a lender maximize recovery on its debt. At other times, an involuntary filing only extends the time until repayment and can impair the lender's position. In this respect, the provisions of the Bankruptcy Code pertaining to Chapter 11 reorganizations can be tools to prevent other creditors from gaining undue advantage or hazards to be avoided, depending on the perspective of the lender. Significant Bankruptcy Code sections include: 1. Section 362, the automatic stay, 2. Sections 363 and 364, restrictions on operation of the business postpetition, 3. Section 547, preferences and fradulent conveyances, 4. Section 510, equitable subordination, and 5. various sections relating to payment of attorneys' fees. In addition to a discussion of when and how to use involuntary bankruptcy as an affirmative strategy, topics covered include techniques for avoiding restraints of bankruptcy initiated by other creditors and the advantages and risks of filing an involuntary petition.

Several recent cases illustrate the potential liability that lenders face in the workout of leveraged buyout (LBO)-related loans. The steps a secured lender can take and other actions it should avoid to minimize its risks when providing LBO financing and when attempting to maximize its recovery if an LBO transaction unravels are described. To provide a compelling defense from possible attack by unsecured creditor committees and others, sophisticated lenders should adopt a comprehensive strategy when providing LBO financing and working out troubled loans arising from such lending. Steps in this strategy include: 1. Review projections skeptically and try to be realistic in evaluating potential earnings. 2. If feasible, insist that all creditors existing at the time of the LBO are paid in full and that all open accounts are reduced to zero. 3. Try to ensure that loan payments can be traced to the collateral. Astute lenders should learn from the rapidly evolving case law and alter their practices accordingly.

HOT FASHION DESIGNERS: Dolce and Gabbana The young Italian duo of Do- menico Dolce and Stefano Gabbana say their clothing is greatly influenced by Italian neo-realism. \"We draw inspiration from the Italian movies of the Forties and Fifties and the works of Federico Fellini, Luchino Visconti and Roberto Rossellini,\" they say.

Compound specific isotopic analysis (CSIA) of amino acids has received increasing attention in ecological studies in recent years due to its ability to evaluate trophic positions and elucidate baseline nutrient sources. However, the incorporation rates of individual amino acids into protein and specific trophic discrimination factors (TDFs) are largely unknown, limiting the application of CSIA to trophic studies. We determined nitrogen turnover rates of individual amino acids from a long-term (up to 1054 days) laboratory experiment using captive Pacific bluefin tuna, Thunnus orientalis (PBFT), a large endothermic pelagic fish fed a controlled diet. Small PBFT (white muscle δ(15)N∼11.5‰) were collected in San Diego, CA and transported to the Tuna Research and Conservation Center (TRCC) where they were fed a controlled diet with high δ(15)N values relative to PBFT white muscle (diet δ(15)N∼13.9‰). Half-lives of trophic and source amino acids ranged from 28.6 to 305.4 days and 67.5 to 136.2 days, respectively. The TDF for the weighted mean values of amino acids was 3.0 ‰, ranging from 2.2 to 15.8 ‰ for individual combinations of 6 trophic and 5 source amino acids. Changes in the δ(15)N values of amino acids across trophic levels are the underlying drivers of the trophic (15)N enrichment. Nearly all amino acid δ(15)N values in this experiment changed exponentially and could be described by a single compartment model. Significant differences in the rate of (15)N incorporation were found for source and trophic amino acids both within and between these groups. Varying half-lives of individual amino acids can be applied to migratory organisms as isotopic clocks, determining the length of time an individual has spent in a new environment. These results greatly enhance the ability to interpret compound specific isotope analyses in trophic studies.